Honokiol for Parkinson's Disease
Also known as: Magnolia bark extract
Honokiol's SIRT3 activation directly addresses mitochondrial dysfunction in Parkinson's dopaminergic neurons.
Mechanism of Action
SIRT3 activation by honokiol enhances mitochondrial SOD2, reduces oxidative damage to Complex I, and promotes mitochondrial quality control. Its anti-inflammatory effects reduce microglial activation in the substantia nigra.
General mechanism: Biphenol from magnolia bark. SIRT3 activator, NF-κB/STAT3 inhibitor, mTOR suppressor. Crosses BBB/BSCB.
Current Evidence
Preclinical models show dopaminergic neuroprotection through SIRT3 pathway. BBB penetrance enables CNS effects. No clinical trials.
Clinical Status: Preclinical. SIRT3-activating mechanism well-characterized.
Safety Profile
Safe in preclinical studies. Long history of use in traditional medicine. Mild sedative effects. Limited human safety data at therapeutic doses.
Key Research Questions
- Does honokiol restore mitochondrial function in PD neurons via SIRT3?
- Can honokiol provide long-term dopaminergic neuroprotection?